MENU
+Compare
XGN
Stock ticker: NASDAQ
AS OF
Dec 26 closing price
Price
$6.13
Change
-$0.06 (-0.97%)
Capitalization
138.92M

XGN Exagen Forecast, Technical & Fundamental Analysis

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases... Show more

XGN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for XGN with price predictions
Dec 26, 2025

XGN's RSI Oscillator is remaining in oversold zone for 2 days

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for XGN just turned positive on December 09, 2025. Looking at past instances where XGN's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XGN advanced for three days, in of 225 cases, the price rose further within the following month. The odds of a continued upward trend are .

XGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for XGN entered a downward trend on December 26, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.657) is normal, around the industry mean (12.326). P/E Ratio (0.000) is within average values for comparable stocks, (130.839). XGN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.860). XGN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (1.954) is also within normal values, averaging (11.828).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. XGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

View a ticker or compare two or three
XGN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

XGN is expected to report earnings to fall 42.29% to -17 cents per share on March 23

Exagen XGN Stock Earnings Reports
Q4'25
Est.
$-0.18
Q3'25
Missed
by $0.15
Q2'25
Missed
by $0.06
Q1'25
Beat
by $0.02
Q4'24
Beat
by $0.12
The last earnings report on November 04 showed earnings per share of -31 cents, missing the estimate of -15 cents. With 227.18K shares outstanding, the current market capitalization sits at 138.92M.
A.I. Advisor
published General Information

General Information

a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
N/A
Address
1261 Liberty Way
Phone
+1 760 560-1501
Employees
179
Web
https://www.exagen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BTQNF45.13N/A
N/A
BQE Water, Inc.
SPSTF0.32N/A
N/A
Singapore Post, Ltd.
NURAF40.19N/A
N/A
Nomura Research Institute Ltd.
RENI0.10N/A
N/A
Resilient Energy Inc.
ALRHF255.09N/A
N/A
Allreal Holding Ag

XGN and Stocks

Correlation & Price change

A.I.dvisor tells us that XGN and NOTV have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XGN and NOTV's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XGN
1D Price
Change %
XGN100%
-2.06%
NOTV - XGN
27%
Poorly correlated
-1.44%
A - XGN
27%
Poorly correlated
-0.03%
QDEL - XGN
26%
Poorly correlated
+1.12%
MXCT - XGN
25%
Poorly correlated
+3.23%
ISRG - XGN
25%
Poorly correlated
-0.03%
More